Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256076 | 1.00 | PDE5A (0.41) | PDE5AGAAMAPTAHRMEN1 | |
| SCHEMBL5917429 | 0.90 | PDE5A (0.44) | PDE5AGAAMAPTAHR | |
| SCHEMBL30357998 | 0.86 | IGF1R (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3256606 | 0.85 | LMNA (0.42) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL7043179 | 0.84 | MAPT (0.41) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5567865 | 0.83 | PDE5A (0.39) | PDE5AGAAMAPTKMT2A | |
| SCHEMBL13889887 | 0.83 | GAA (0.42) | GAAMAPTAHRALDH1A1 | |
| SCHEMBL1760643 | 0.82 | ALDH1A1 (0.44) | GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6974512 | 0.82 | GAA (0.40) | GAAMAPTKMT2AALDH1A1 | |
| SCHEMBL5567814 | 0.82 | ALDH1A1 (0.44) | GAAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042288-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | INST NAT SANTE RECH MED (FR) | 2007-11-07 | — | — | EP | disclosed |
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
| US-6335360-B1 | INDOLINE-2-CARBOXYLIC AMIDE DERIVATIVES; OBESITY, EATING AND PSYCHOLOGICAL DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-01 | — | — | US | disclosed |
| EP-1042288-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033801-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | PDE5A 902/4885GAA 67/4885MAPT 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.